(E)-ethyl 3-(5-methylpyridin-2-yl)acrylate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-ethyl 3-(5-methylpyridin-2-yl)acrylate
• 英文别名: (E)-Ethyl 3-(5-methylpyridin-2-yl)acrylate；ethyl (E)-3-(5-methylpyridin-2-yl)prop-2-enoate
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: MNWGHICRWMFWAT-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-溴-2-吡啶甲醛 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium hydride 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 1.5h， 生成 (E)-ethyl 3-(5-methylpyridin-2-yl)acrylate
  参考文献：
  名称：

  ARYLOXYMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS

  摘要：

  公开号：

  EP2714041B1

文献信息

• ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS
  申请人：Breslin Michael J.

  公开号：US20140336195A1

  公开（公告）日：2014-11-13

  The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及芳氧甲基环丙烷衍生物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这些化合物治疗神经系统和精神疾病，如精神分裂症、精神病或亨廷顿病等与纹状体低功能或基底节功能障碍有关的疾病。
• Ligand-Promoted C-3 Selective C–H Olefination of Pyridines with Pd Catalysts
  作者：Mengchun Ye、Guo-Lin Gao、Jin-Quan Yu

  DOI：10.1021/ja2021075

  日期：2011.5.11

  Pd-catalyzed C-3 selective olefination of pyridines is developed for the first time using 1,10-phenanthroline as the ligand. This finding provides a novel disconnection for the synthesis of pyridine-containing alkaloids and drug molecules as well as a new approach for developing Pd-catalyzed C H functionalizations of pyridines.
• US8975261B2
  申请人：——

  公开号：US8975261B2

  公开（公告）日：2015-03-10
• [EN] ARYLOXYMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS<br/>[FR] DÉRIVÉS D'ARYLOXYMÉTHYL CYCLOPROPANE EN TANT QU'INHIBITEURS DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2012162213A1

  公开（公告）日：2012-11-29

  The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
• ARYLOXYMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2714041B1

  公开（公告）日：2016-10-19